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The current timeline for manufacturing high-quality recombinant proteins used for therapeutics and vaccines, and 
delivering them to patients, typically requires many months.  There are many circumstances, however, where the 
rapid production, release, and delivery of these biologics could address unmet medical needs, including 
shortages, emergency situations, and pandemics.  This talk will present a new platform developed to produce 
biologic medicines on demand called Integrated and Scalable Cyto-Technology (InSCyT).  This platform 
comprises an integrated, subliter-scale portable system for the (semi)continuous operation of fermentation, 
filtration of cell debris from secreted product, innovative affinity-based purification, polishing, and finishing.  This 
program also emphasizes integrated on-line PAT and process control for QbD production and product qualification 
for release.  Examples of the underlying technologies enabling this platform will be presented, along with examples 
of its integrated operation to produce multiple high-quality recombinant proteins on the same platform, each in 
less than 48 hours from initial seed to dose.   
 
Beyond the applications for rapid manufacturing of biologics at point-of-care, the speed of production enabled by 
automation and integration highlights other opportunities for vaccine development and conventional 
manufacturing.  These include modeling complete manufacturing processes during process development, rapidly 
creating materials for preclinical and early-stage clinical testing, and manufacturing therapies for orphan diseases, 
among others.  
 
